Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Glucose-6-Phosphate Dehydrogenase from the Human Pathogen Trypanosoma cruzi Evolved Unique Structural Features to Support Efficient Product Formation.

Ortíz C, Botti H, Buschiazzo A, Comini MA.

J Mol Biol. 2019 Mar 28. pii: S0022-2836(18)30691-0. doi: 10.1016/j.jmb.2019.03.023. [Epub ahead of print]

PMID:
30930048
2.

Potential sexual transmission of Giardia in an endemic region: a case series.

Escobedo AA, Acosta-Ballester G, Almirall P, Rodriguez-Morales AJ, Ortíz C, Laffita A, Chirino E.

Infez Med. 2018 Jun 1;26(2):171-175.

3.

Binding Mode and Selectivity of Steroids towards Glucose-6-phosphate Dehydrogenase from the Pathogen Trypanosoma cruzi.

Ortiz C, Moraca F, Medeiros A, Botta M, Hamilton N, Comini MA.

Molecules. 2016 Mar 17;21(3):368. doi: 10.3390/molecules21030368.

4.

HCV-induced immune responses influence the development of operational tolerance after liver transplantation in humans.

Bohne F, Londoño MC, Benítez C, Miquel R, Martínez-Llordella M, Russo C, Ortiz C, Bonaccorsi-Riani E, Brander C, Bauer T, Protzer U, Jaeckel E, Taubert R, Forns X, Navasa M, Berenguer M, Rimola A, Lozano JJ, Sánchez-Fueyo A.

Sci Transl Med. 2014 Jun 25;6(242):242ra81. doi: 10.1126/scitranslmed.3008793.

5.

[Antimicrobial susceptibility and genetic bases for resistance of infection-causing Enterococcus strains in Cuba].

Quiñones Pérez D, Abreu Capote M, Marrero D, Alvarez AB, Ortiz C, Salomé F, Llop A, Campo Rd.

Rev Panam Salud Publica. 2011 Dec;30(6):549-54. Spanish.

PMID:
22358401
6.

Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy.

Berenguer M, Aguilera V, Rubín A, Ortíz C, Jimenez M, Prieto M.

J Hepatol. 2012 Jun;56(6):1310-6. doi: 10.1016/j.jhep.2011.12.031. Epub 2012 Feb 5.

PMID:
22314429
7.

Expression, crystallization and preliminary X-ray crystallographic analysis of glucose-6-phosphate dehydrogenase from the human pathogen Trypanosoma cruzi in complex with substrate.

Ortíz C, Larrieux N, Medeiros A, Botti H, Comini M, Buschiazzo A.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 Nov 1;67(Pt 11):1457-61. doi: 10.1107/S1744309111037821. Epub 2011 Oct 27. Erratum in: Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 Dec 1;67(Pt 12):1674.

8.

Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin.

Giusto M, Rodriguez M, Navarro L, Rubin A, Aguilera V, San-Juan F, Ortiz C, López-Andujar R, Prieto M, Berenguer M.

Liver Transpl. 2011 Nov;17(11):1318-27. doi: 10.1002/lt.22387.

9.

Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis.

Berenguer M, Aguilera V, Prieto M, Ortiz C, Rodríguez M, Gentili F, Risalde B, Rubin A, Cañada R, Palau A, Rayón JM.

Liver Transpl. 2009 Jul;15(7):738-46. doi: 10.1002/lt.21707.

10.

The peroxidase and peroxynitrite reductase activity of human erythrocyte peroxiredoxin 2.

Manta B, Hugo M, Ortiz C, Ferrer-Sueta G, Trujillo M, Denicola A.

Arch Biochem Biophys. 2009 Apr 15;484(2):146-54. doi: 10.1016/j.abb.2008.11.017. Epub 2008 Nov 24.

PMID:
19061854

Supplemental Content

Loading ...
Support Center